CompletedPhase 3

Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®

France76 participantsStarted 2010-08

Plain-language summary

The aim of this randomized trial is to compare the rate of radio-dermatitis grade 2+ (NCI-CTC V3.0) in patients receiving radiotherapy+Erbitux+placebo versus in patients receiving radiotherapy+Erbitux+OTD70DERM® for the treatment of head and neck carcinoma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Head and neck carcinoma treated by radiotherapy (70Gy) plus Erbitux Exclusion Criteria: * IMRT; Concomitant chemotherapy

What they're measuring

Radio-dermatitis grade 2, 3, 4 (NCI-CTC V3)

Timeframe: 3 months

Trial details

NCT IDNCT01228565

SponsorGroupe Oncologie Radiotherapie Tete et Cou

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-05

View on ClinicalTrials.gov More Head and Neck Carcinoma trials